

**CD82 (ST6) Antibody (C-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP6250a****Specification**

---

**CD82 (ST6) Antibody (C-term) Blocking peptide - Product Information**

Primary Accession [P27701](#)  
Other Accession [NP\\_002222](#)

**CD82 (ST6) Antibody (C-term) Blocking peptide - Additional Information**

**Gene ID** 3732

**Other Names**

CD82 antigen, C33 antigen, IA4, Inducible membrane protein R2, Metastasis suppressor Kangai-1, Suppressor of tumorigenicity 6 protein, Tetraspanin-27, Tspan-27, CD82, CD82, KAI1, SAR2, ST6, TSPAN27

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP6250a](/product/products/AP6250a) was selected from the C-term region of human ST6. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**CD82 (ST6) Antibody (C-term) Blocking peptide - Protein Information**

**Name** CD82

**Synonyms** KAI1, SAR2, ST6, TSPAN27

**Function**

Associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway.

**Cellular Location**

Cell membrane; Multi-pass membrane protein

**Tissue Location**

Lymphoid specific.

**CD82 (ST6) Antibody (C-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**CD82 (ST6) Antibody (C-term) Blocking peptide - Images****CD82 (ST6) Antibody (C-term) Blocking peptide - Background**

The ST6 metastasis suppressor gene product is a membrane glycoprotein that is a member of the transmembrane 4 superfamily. Expression has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients.

**CD82 (ST6) Antibody (C-term) Blocking peptide - References**

Zhang, X.A., et al., J. Biol. Chem. 278(29):27319-27328 (2003). Zhang, X.A., et al., Cancer Res. 63(10):2665-2674 (2003). Yang, J., et al., Ai Zheng 22(5):533-536 (2003). Sauer, G., et al., Oncol. Rep. 10(2):405-410 (2003). Ito, Y., et al., Pathol Res Pract 199(2):79-83 (2003).